Table 2 Univariate and multivariate analyses of intrahepatic cholangiocarcinoma
OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR | P | HR | P | HR | P | HR | P | |
LND | ||||||||
No | 1 | < 0.01 | 1 | 0.71 | 1 | < 0.01 | 1 | 0.22 |
Yes | 1.751 (1.157–2.650) | 0.909 (0.548–1.508) | 1.896 (1.259–2.857) | 1.357 (0.838–2.197) | ||||
Sex | ||||||||
Female | 1 | 0.91 | 1 | 0.94 | ||||
Male | 1.021 (0.728–1.431) | 1.013 (0.734–1.397) | ||||||
Age (year) | ||||||||
≤ 60 | 1 | 0.44 | 1 | 0.33 | ||||
> 60 | 0.873 (0.619–1.230) | 0.850 (0.613–1.179) | ||||||
POD time (day) | ||||||||
≤ 9 | 1 | < 0.01 | 1 | 0.24 | 1 | 0.057 | 1 | 0.37 |
> 9 | 2.050 (1.447–2.906) | 1.299 (0.836–2.019) | 1.369 (0.990–1.893) | 1.215 (0.795–1.858) | ||||
HbsAg + | ||||||||
No | 1 | 0.45 | 1 | 0.49 | ||||
Yes | 0.839 (0.530–1.329) | 1.151 (0.770–1.722) | ||||||
CEA (ng/mL) | ||||||||
≤ 7 | 1 | < 0.01 | 1 | < 0.01 | 1 | < 0.01 | 1 | 0.04 |
> 7 | 3.801 (2.526–5.718) | 2.117 (1.288–3.480) | 2.461 (1.623–3.731) | 1.677 (1.035–2.716 | ||||
CA199 (U/mL) | ||||||||
≤ 75 | 1 | < 0.01 | 1 | 0.03 | 1 | < 0.01 | 1 | 0.13 |
> 75 | 2.421 (1.691–3.465) | 1.565 (1.044–2.346) | 1.877 (1.339–2.631) | 1.355 (0.918–2.001) | ||||
Operation time (min) | ||||||||
≤ 235 | 1 | < 0.01 | 1 | 0.07 | 1 | < 0.01 | 1 | 0.37 |
> 235 | 2.148 (1.523–3.029) | 1.529 (0.974–2.398) | 1.661 (1.200–2.299) | 1.210 (0.797–1.836) | ||||
Blood loss (mL) | ||||||||
≤ 300 | 1 | < 0.01 | 1 | 0.48 | 1 | < 0.01 | 1 | 0.64 |
> 300 | 2.058 (1.465–2.891) | 1.207 (0.719–2.026) | 1.541 (1.116–2.126) | 1.103 (0.728–1.673) | ||||
Intraoperative blood transform | ||||||||
No | 1 | < 0.01 | 1 | 0.37 | 1 | 0.26 | ||
Yes | 1.944 (1.381–2.735) | 0.760 (0.419–1.379) | 1.215 (0.869–1.699) | |||||
Tumor size (cm) | ||||||||
≤ 6 | 1 | 0.03 | 1 | 0.09 | 1 | 0.04 | 1 | 0.18 |
> 6 | 1.454 (1.038–2.036) | 1.408 (0.949–2.088) | 1.405 (1.018–1.938) | 1.275 (0.893–1.819) | ||||
Multi-disease | ||||||||
No | 1 | < 0.01 | 1 | 0.15 | 1 | < 0.01 | 1 | 0.12 |
Yes | 2.017 (1.361–2.989) | 1.467 (0.868–2.481) | 1.809 (1.215–2.692) | 1.507 (0.903–2.516) | ||||
Margin + | ||||||||
No | 1 | < 0.01 | 1 | < 0.01 | 1 | < 0.01 | 1 | 0.10 |
Yes | 2.566 (1.588–4.148) | 2.908 (1.642–5.152) | 1.977 (1.229–3.181) | 1.617 (0.916–2.855) | ||||
Differentiation | ||||||||
Moderately + well | 1 | 1 | 1 | |||||
Poorly | 1.096 (0.775–1.550) | 0.61 | 1.438 (1.039–1.989) | 0.03 | 1.583 (1.071–2.341) | 0.02 | ||
Vascular invasion | ||||||||
No | 1 | 0.01 | 1 | 0.56 | 1 | < 0.01 | 1 | 0.70 |
Yes | 1.891 (1.350–2.650) | 1.146 (0.728–1.802) | 1.642 (1.189–2.267) | 1.090 (0.710–1.674) | ||||
Nerve invasion | ||||||||
No | 1 | < 0.01 | 1 | 0.16 | 1 | < 0.01 | 1 | 0.12 |
Yes | 1.808 (1.259–2.599) | 1.387 (0.877–2.194) | 1.747 (1.240–2.461) | 1.340 (0.874–2.054) | ||||
T state | ||||||||
T1 | 1 | < 0.01 | 1 | 0.03 | 1 | < 0.01 | 1 | 0.78 |
> T1 | 2.494 (1.776–3.504) | 1.747 (1.071–2.848) | 1.652 (1.185–2.302) | 0.936 (0.594–1.476) | ||||
Adjuvant chemotherapy | ||||||||
No | 1 | 0.09 | 1 | 0.78 | ||||
Yes | 0.741 (0.526–1.044) | 0.953 (0.683–1.331) | ||||||
ASA | ||||||||
≤ 2 | 1 | 0.60 | 1 | 0.70 | ||||
> 2 | 0.849 (0.458–1.574) | 1.113 (0.641–1.932) | ||||||
BMI (kg/m2) | ||||||||
< 25 | 1 | 0.78 | 1 | 0.75 | ||||
≥ 25 | 1.050 (0.748–1.474) | 0.948 (0.685–1.311) | ||||||
Cirrhosis | ||||||||
No | 1 | 0.14 | 1 | |||||
Yes | 1.423 (0.893–2.268) | 0.884 (0.592–1.320) | ||||||
Comorbidity | ||||||||
No | 1 | 0.16 | 1 | 0.99 | ||||
Yes | 0.780 (0.554–1.098) | 1.003 (0.726–1.384) | ||||||
ALT (U/L) | ||||||||
≤ 50 | 1 | < 0.01 | 1 | 0.91 | 1 | 0.94 | ||
> 50 | 2.049 (1.379–3.045) | 1.034 (0.578–1.850) | 0.984 (0.634–1.526) | |||||
TBIL (ALB) | ||||||||
1 | 0.05 | 1 | 0.95 | 1 | 0.54 | |||
1.526 (1.006–2.313) | 1.020 (0.571–1.821) | 0.865 (0.545–1.372) | ||||||
ALB (g/L) | ||||||||
≥ 35 | 1 | < 0.01 | 1 | 0.19 | 1 | 0.93 | ||
< 35 | 2.458 (1.450–4.168) | 1.628 (0.791–3.354) | 0.970 (0.509–1.846) | |||||